Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives

In the last 20 years the clinical management of patients with advanced non-small cell lung cancer (NSCLC) has shifted form a histology-driven to a molecularly-based approach due to the identification of actionable genetic alterations and the subsequent development of highly efficacious targeted therapies.